Biotech | March 10, 2022
Pfizer initiates Phase2/3 study of Paxlovid in pediatric participants
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers
The first wave of shipments includes several countries, such as Germany, France and Austria
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
The recommendation has been sent to the DCGI for approval
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
It has signed an MoU with Plan India to expand its reach to Karnataka
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
Subscribe To Our Newsletter & Stay Updated
